Home   About this service   Get the news  
+32 2 743 34 03

 
UCB [BE0003739530 / UCB]

UCB Media Room: UCB updates its financial outlook for 2019

INFORMATION REGLEMENTEE


[10/01/2020 | 18:10]
https://mb.cision.com/Public/18595/3006365/8f39e7cbf3662ca0_800x800ar.jpg

** UCB updates its financial outlook for 2019
------------------------------------------------------------

=C2=B7 Stronger than expected net sales lead to higher earnings level in 20=
19
=C2=B7 UCB=E2=80=99s Full Year 2019 results will be presented on 20 Februar=
y 2020

Brussels, Belgium 10 January 2020, 18:00 CET, regulated information =E2=80=
=93 inside information =E2=80=93 unaudited financials - UCB, a global bioph=
armaceutical company, today announced an updated financial outlook for 2019:

=C2=B7 Total revenue in 2019 are expected to reach approx. =E2=82=AC 4.9bn =
=E2=80=93 previous outlook was in the range of =E2=82=AC 4.6 =E2=80=93 4.7b=
n.=C2=A0
=C2=B7 The underlying profitability (recurring EBITDA) is now expected at l=
east at the upper end of the range of 27% - 29% of revenue - previous guida=
nce was in the range of 27% =E2=80=93 29%.=C2=A0
=C2=B7 Also the Core EPS are now expected to be higher than =E2=82=AC 4.80 =
=E2=80=93 previous range was =E2=82=AC 4.40 =E2=80=93 4.80

These changes are driven by better than expected net sales, due to strong d=
emand for Cimzia^=C2=AE and Vimpat^=C2=AE in the fourth quarter 2019. To op=
timize the growth opportunity additional marketing activities were funded.

The full financial statements for 2019 will be published on 20 February 202=
0.=C2=A0

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With more than 7 500 people in=
approximately 40 countries, UCB generated revenue of =E2=82=AC 4.6 billion=
in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Tw=
itter: @UCB_news

For further information, UCB:

Corporate Communications
Laurent Schots=C2=A0
Media Relations, UCB =C2=A0
T+32.2.559.92.64 =C2=A0Laurent.schots@ucb.com=C2=A0

Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
=C2=A0Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0

Forward looking statements UCB
This press release contains forward-looking statements including, without l=
imitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =E2=
=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=E2=
=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestimate=
s=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccontinu=
e=E2=80=9D and similar expressions. These forward-looking statements are ba=
sed on current plans, estimates and beliefs of management. All statements, =
other than statements of historical facts, are statements that could be dee=
med forward-looking statements, including estimates of revenues, operating =
margins, capital expenditures, cash, other financial information, expected =
legal, arbitration, political, regulatory or clinical results or practices =
and other such estimates and results. By their nature, such forward-looking=
statements are not guarantees of future performance and are subject to kno=
wn and unknown risks, uncertainties and assumptions which might cause the a=
ctual results, financial condition, performance or achievements of UCB, or =
industry results, to differ materially from those that may be expressed or =
implied by such forward-looking statements contained in this press release.=
Important factors that could result in such differences include: changes i=
n general economic, business and competitive conditions, the inability to o=
btain necessary regulatory approvals or to obtain them on acceptable terms =
or within expected timing, costs associated with research and development, =
changes in the prospects for products in the pipeline or under development =
by UCB, effects of future judicial decisions or governmental investigations=
, safety, quality, data integrity or manufacturing issues; potential or act=
ual data security and data privacy breaches, or disruptions of our informat=
ion technology systems, product liability claims, challenges to patent prot=
ection for products or product candidates, competition from other products =
including biosimilars, changes in laws or regulations, exchange rate fluctu=
ations, changes or uncertainties in tax laws or the administration of such =
laws, and hiring and retention of its employees. There is no guarantee that=
new product candidates will be discovered or identified in the pipeline, o=
r that new indications for existing products will be developed and approved=
. Movement from concept to commercial product is uncertain; preclinical res=
ults do not guarantee safety and efficacy of product candidates in humans. =
So far, the complexity of the human body cannot be reproduced in computer m=
odels, cell culture systems or animal models. The length of the timing to c=
omplete clinical trials and to get regulatory approval for product marketin=
g has varied in the past and UCB expects similar unpredictability going for=
ward. Products or potential products which are the subject of partnerships,=
joint ventures or licensing collaborations may be subject to disputes betw=
een the partners or may prove to be not as safe, effective or commercially =
successful as UCB may have believed at the start of such partnership. UCB=
=E2=80=99 efforts to acquire other products or companies and to integrate t=
he operations of such acquired companies may not be as successful as UCB ma=
y have believed at the moment of acquisition. Also, UCB or others could dis=
cover safety, side effects or manufacturing problems with its products and/=
or devices after they are marketed. The discovery of significant problems w=
ith a product similar to one of UCB=E2=80=99s products that implicate an en=
tire class of products may have a material adverse effect on sales of the e=
ntire class of affected products. Moreover, sales may be impacted by intern=
ational and domestic trends toward managed care and health care cost contai=
nment, including pricing pressure, political and public scrutiny, customer =
and prescriber patterns or practices, and the reimbursement policies impose=
d by third-party payers as well as legislation affecting biopharmaceutical =
pricing and reimbursement activities and outcomes. Finally, a breakdown, cy=
berattack or information security breach could compromise the confidentiali=
ty, integrity and availability of UCB=E2=80=99s data and systems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and expressly disclaims any duty to=
update any information contained in this press release, either to confirm =
the actual results or to report or reflect any change in its forward-lookin=
g statements with regard thereto or any change in events, conditions or cir=
cumstances on which any such statement is based, unless such statement is r=
equired pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.

GenericFile
UCB updated outlook press release ENG (https://mb.cision.com/Public/18595/3=
006365/83ee552bedcf482e.pdf)=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x33214x1x6868579x24000=
x6&Email=3Dregnews%40symexglobal.com.=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=